Your browser doesn't support javascript.
loading
Design driven HtL: The discovery and synthesis of new high efficacy ß2-agonists.
Stocks, Michael J; Alcaraz, Lilian; Bailey, Andrew; Bonnert, Roger; Cadogan, Elaine; Christie, Jadeen; Connolly, Stephen; Cook, Anthony; Fisher, Adrian; Flaherty, Alice; Hill, Stephen; Humphries, Alexander; Ingall, Anthony; Jordan, Stephen; Lawson, Mandy; Mullen, Alex; Nicholls, David; Paine, Stuart; Pairaudeau, Garry; St-Gallay, Stephen; Young, Alan.
Affiliation
  • Stocks MJ; Department of Medicinal Chemistry, AstraZeneca R&D Charnwood, Bakewell Road, Loughborough, Leicestershire LE11 5RH, UK. mike.stocks@astrazeneca.com
Bioorg Med Chem Lett ; 21(13): 4027-31, 2011 Jul 01.
Article in En | MEDLINE | ID: mdl-21652207
ABSTRACT
The design and synthesis of a new series of high efficacy ß(2)-agonists devoid of the key benzylic alcohol present in previously described highly efficacious ß(2)-agonists is reported. A hypothesis for the unprecedented level of efficacy is proposed based on considerations of ß(2)-adrenoceptor crystal structure, other biophysical data and modeling studies.
Subject(s)

Full text: 1 Database: MEDLINE Main subject: Drug Design / Adrenergic beta-2 Receptor Agonists Limits: Animals / Humans Language: En Year: 2011 Type: Article

Full text: 1 Database: MEDLINE Main subject: Drug Design / Adrenergic beta-2 Receptor Agonists Limits: Animals / Humans Language: En Year: 2011 Type: Article